It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for its potential as a therapy for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.